US-based Zydus Pharmaceuticals, a subsidiary of Cadila Healthcare, (Q, N,C,F)* has received final approval from the US Food and Drug Administration (USFDA) to market Acetazolamide capsules, in the strength of 500 mg.

Acetazolamide is a carbonic anhydrase inhibitor used to treat certain types of glaucoma, epilepsy, or edema (fluid buildup) in combination with other medicines.

Acetazolamide also increases the removal of water from the body by the kidney. It may also be used to treat other conditions.

Shares of Cadila Healthcare closed up Rs 0.55, or 0.21%, at Rs 265.75. The total volume of shares traded at the BSE was 1,031 (Wednesday).